These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10179707)

  • 1. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study.
    Schädlich PK; Brecht JG
    Pharmacoeconomics; 1998 Jun; 13(6):719-30. PubMed ID: 10179707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate.
    Palmer AJ; Neeser K; Weiss C; Brandt A; Comte S; Fox M
    Alcohol Alcohol; 2000; 35(5):478-92. PubMed ID: 11022023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acamprosate. Pharmacoeconomic implications of therapy.
    Foster RH; McClellan KJ
    Pharmacoeconomics; 1999 Dec; 16(6):743-55. PubMed ID: 10724798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of Campral (Acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients.
    Annemans L; Vanoverbeke N; Tecco J; D'Hooghe D
    Eur Addict Res; 2000 Jun; 6(2):71-8. PubMed ID: 10899732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adjuvant drug treatment of alcoholism with acamprosate: between sectoral budgets and disease management].
    Rychlik R; Paschen B; Kirchhoff D; Daniel D; Pfeil T; Kilburg A
    Dtsch Med Wochenschr; 2001 Aug; 126(33):899-904. PubMed ID: 11514924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients.
    Rychlik R; Siedentop H; Pfeil T; Daniel D
    Eur Addict Res; 2003 Apr; 9(2):59-64. PubMed ID: 12644731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical review of pharmacoeconomic studies of acamprosate.
    Poldrugo F; Haeger DA; Comte S; Walburg J; Palmer AJ
    Alcohol Alcohol; 2005; 40(5):422-30. PubMed ID: 15939706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
    Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
    Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study.
    Soyka M; Preuss U; Schuetz C
    Drugs R D; 2002; 3(1):1-12. PubMed ID: 11881521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.
    Dunlap LJ; Zarkin GA; Bray JW; Mills M; Kivlahan DR; McKay JR; Latham P; Tonigan JS
    Med Care; 2010 Apr; 48(4):306-13. PubMed ID: 20355261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A literature review of cost-benefit analyses for the treatment of alcohol dependence.
    Popova S; Mohapatra S; Patra J; Duhig A; Rehm J
    Int J Environ Res Public Health; 2011 Aug; 8(8):3351-64. PubMed ID: 21909311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acamprosate for the adjunctive treatment of alcohol dependence.
    Overman GP; Teter CJ; Guthrie SK
    Ann Pharmacother; 2003; 37(7-8):1090-9. PubMed ID: 12841823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring economic outcomes of alcohol treatment using the Economic Form 90.
    Bray JW; Zarkin GA; Miller WR; Mitra D; Kivlahan DR; Martin DJ; Couper DJ; Cisler RA
    J Stud Alcohol Drugs; 2007 Mar; 68(2):248-55. PubMed ID: 17286343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
    Doran CM; Fawcett JE; Shakeshaft AP; Shanahan MD; Mattick RP
    Med J Aust; 2003 Aug; 179(4):218. PubMed ID: 12914502
    [No Abstract]   [Full Text] [Related]  

  • 15. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
    Baser O; Chalk M; Rawson R; Gastfriend DR
    Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficient prevention of relapse with acamprosate].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2000 Jun; 23(6):206-7. PubMed ID: 10950666
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.
    Schädlich PK; Huppertz E; Brecht JG
    Pharmacoeconomics; 1998 Dec; 14(6):653-69. PubMed ID: 10346417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acamprosate for the treatment of alcohol dependence.
    Boothby LA; Doering PL
    Clin Ther; 2005 Jun; 27(6):695-714. PubMed ID: 16117977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care.
    Kiritzé-Topor P; Huas D; Rosenzweig C; Comte S; Paille F; Lehert P
    Alcohol Alcohol; 2004; 39(6):520-7. PubMed ID: 15304381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved autonomic neurocardial balance in short-term abstinent alcoholics treated with acamprosate.
    Agelink MW; Lemmer W; Malessa R; Zeit T; Majewski T; Klieser E
    Alcohol Alcohol; 1998; 33(6):602-5. PubMed ID: 9872347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.